Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D

Schizophrenia Research

Volumn 89, Issue 1-3, 2007, Pages 147-153

  Thomas, Elizabeth A ^a   Yao, Jeffrey K ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; Apolipoprotein; Arachidonic acid; Clozapine; Fatty acid; HPLC

Indexed keywords

ADRENIC ACID; APOLIPOPROTEIN D; ARACHIDIC ACID; ARACHIDONIC ACID; CLOZAPINE; DOCOSAHEXAENOIC ACID; FATTY ACID; LINOLEIC ACID; MEMBRANE LIPID; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAPILLARY GAS CHROMATOGRAPHY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; FATTY ACID BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RODENT; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOLIPOPROTEINS D; ARACHIDONIC ACID; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; ERUCIC ACIDS; FATTY ACIDS; LINOLEIC ACID; MEMBRANE LIPIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSENCEPHALON;

EID: 33845296111     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.08.011     Document Type: Article

References (33)

1. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., and Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 53 (2003) 56-64
2. Dilley W.G., Haagensen D.E., Cox C.E., and Wells S.A. Immunologic and steroid binding properties of CDFP-24 protein isolated from human breast gross cystic disease fluid. Breast Cancer Res. Treat. 16 (1990) 253-260
3. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., and Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot. Essent. Fat. Acids 69 (2003) 393-399
4. Grobin A., Gizerian S., and Lieberman J. Olanzapine Increases Apolipoprotein D Protein Levels in Rat Frontal Cortex (2003), Society for Neuroscience, Washington DC
5. Horrobin D.F., Glen A.I.M., and Cantrill R.C. Clozapine: elevation of membrane unsaturated lipid levels as a new mechanism of action. Schizophr. Res. 24 (1997) 214
6. Kemperman R.F., Veurink M., van der Wal T., Knegtering H., Bruggeman R., Fokkema M.R., Kema I.P., Korf J., and Muskiet F.A. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukot. Essent. Fat. Acids 74 (2006) 75-85
7. Khan M.M., Parikh V.V., and Mahadik S.P. Effects of chronic exposure of antipsychotics on apolipoprotein D in rat brain. Biol. Psychiatry 51 (2002) 168S
8. Khan M.M., Parikh V.V., and Mahadik S.P. Antipsychotic drugs differentially modulate apolipoprotein D in rat brain. J. Neurochem. 86 (2003) 1089-1100
9. Lea O.A. Binding properties of progesterone-binding cyst protein PBCP. Steroids 52 (1988) 337-338
10. Mahadik S.P., Mukherjee S., Correnti E.E., and Scheffer R. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar and normal controls. Psychiatry Res. 63 (1996) 133-142
11. Mahadik S.P., Khan M.M., Evans D.R., and Parikh V.V. Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome. Schizophr. Res. 58 (2002) 55-62
12. Morais-Cabral J.H., Atkins G.L., Sanchez L.M., Lopez-Boado Y.S., Lopez-Otin C., and Sawyer L. Arachidonic acid binds to apoliprotein D: implications for the protein's function. FEBS Lett. 366 (1995) 53-56
13. Patel R., Lange D., McConathy W.J., Patel Y.C., and Patel S.C. Probing the structure of the ligand binding cavity of lipocalins by fluorescence spectroscopy. Protein Eng. 10 (1997) 621-625
14. Pearlman W.H., Gueriguian J.L., and Sawyer M.E. A specific progesterone-binding component of human breast cyst fluid. J. Biol. Chem. 248 (1973) 5736-5741
15. Peet M., Laugharne J.D.E., Rangarajan N., Horrobin D.F., and Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 29 (1995) 227-232
16. Peitsch M.C., and Boguski M.S. Is apolipoprotein D a mammalian bilin-binding protein?. New Biol. 2 (1990) 197-206
17. Rassart E., Bedirian A., Do Carmo S., Guinard O., Sirois J., Terrisse L., and Milne R. Apolipoprotein D. Biochim. Biophys. Acta 1482 (2000) 185-198
18. Reddy R.D., Keshavan M.S., and Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 30 (2004) 901-911
19. Sanchez D., Lopez-Arias B., Torroja L., Canal I., Wang X., Bastiani M.J., and Ganfornina M.D. Loss of glial lazarillo, a homolog of apolipoprotein d, reduces lifespan and stress resistance in Drosophila. Curr. Biol. 16 (2006) 680-686
20. Skosnik P.D., and Yao J.K. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?. Prostaglandins Leukot. Essent. Fat. Acids 69 (2003) 367-384
21. Sutcliffe J.G., and Thomas E.A. The neurobiology of apolipoproteins in psychiatric disorders. Mol. Neurobiol. 26 (2002) 369-388
22. Thomas E.A., Danielson P.E., Nelson P.A., Pribyl T.M., Hilbush B.S., Hasel K.W., and Sutcliffe J.G. Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. J. Neurochem. 76 (2001) 789-796
23. Thomas E.A., Dean B., Pavey G., and Sutcliffe J.G. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4066-4071
24. Thomas E.A., Copolov D.L., and Sutcliffe J.G. From pharmacotherapy to pathophysiology: emerging mechanisms of apolipoprotein D in psychiatric disorders. Curr. Mol. Med. 3 (2003) 408-418
25. Thomas, E.A., George, R.C., Danielson, P.E., Nelson, P.A., Warren, A.J., Lo, D., Sutcliffe, J.G., 2003b. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol. Psychiatry 8: 983-93, 950.
26. Thomas E.A., George R.C., and Sutcliffe J.G. Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders. Prostaglandins Leukot. Essent. Fat. Acids 69, 421-427. (2003)
27. Thomas, E.A., Dean, B., Scarr, E., Copolov, D., Sutcliffe, J.G., 2003d. Differences in neuroanatomical sites of ApoD elevation discriminate between schizophrenia and bipolar disorder. Mol. Psychiatry 8, 167-175.
28. Vogt M., and Skerra A. Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H. J. Mol. Recognit. 14 (2001) 79-86
29. Xu S., and Venge P. Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta 18 (2000) 1-2
30. Yao J.K., van Kammen D.P., and Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 13 (1994) 217-226
31. Yao J.K., Leonard S., and Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42 (2000) 7-17
32. Yao J.K., Thomas E.A., Reddy R.D., and Keshavan M.S. Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophr. Res. 72 (2005) 259-266
33. Zeng C., Spielman A.I., Vowels B.R., Leyden J.J., Biemann K., and Preti G. A human axillary odorant is carried by apolipoprotein D. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 6626-6630